Scientists Test Medicinal Marijuana Against MS, Inflammation and Cancer

By Nathan Seppa

In science’s struggle to keep up with life on the streets, smoking cannabis for medical purposes stands as Exhibit A.

Medical use of cannabis has taken on momentum of its own, surging ahead of scientists’ ability to measure the drug’s benefits. The pace has been a little too quick for some, who see medicinal joints as a punch line, a ruse to free up access to a recreational drug.

But while the medical marijuana movement has been generating political news, some researchers have been quietly moving in new directions — testing cannabis and its derivatives against a host of diseases. The scientific literature now brims with potential uses for cannabis that extend beyond its well-known abilities to fend off nausea and block pain in people with cancer and AIDS. Cannabis derivatives may combat multiple sclerosis, Crohn’s disease and other inflammatory conditions, the new research finds. Cannabis may even kill cancerous tumors.

Many in the scientific community are now keen to see if this potential will be fulfilled, but they haven’t always been. Pharmacologist Roger Pertwee of the University of Aberdeen in Scotland recalls attending scientific conferences 30 years ago, eager to present his latest findings on the therapeutic effects of cannabis. It was a hard sell.

“Our talks would be scheduled at the end of the day, and our posters would be stuck in the corner somewhere,” he says. “That’s all changed.”

 

Underlying biology

The long march to credibility for cannabis research has been built on molecular biology. Smoking or otherwise consuming marijuana — Latin name Cannabis sativa — has a medical history that dates back thousands of years. But the euphoria-inducing component of cannabis, delta-9-tetrahydrocannabinol, or THC, wasn’t isolated until 1964, by biochemist Raphael Mechoulam, then of the Weizmann Institute of Science in Rehovot, Israel, and his colleagues. Within two decades, other researchers had developed synthetic THC to use in pill form.

The secrets of how THC worked in the body lay hidden until the late 1980s, when researchers working with rats found that the compound binds to a protein that pops up on the surface of nerve cells. Further tests showed that THC also hooks up with another protein found elsewhere in the body. These receptor proteins were dubbed CB1 and CB2.

A bigger revelation came in 1992: Mammals make their own compound that binds to, and switches on, the CB1 receptor. Scientists named the compound anandamide. Researchers soon found its counterpart that binds mainly to the CB2 receptor, calling that one 2AG, for 2-arachidonyl glycerol. The body routinely makes these compounds, called endocannabinoids, and sends them into action as needed.

“At that point, this became a very, very respectable field,” says Mechoulam, now at Hebrew University of Jerusalem, who along with Pertwee and others reported the anandamide discovery in Science. “THC just mimics the effects of these compounds in our bodies,” Mechoulam says. Although the receptors are abundant, anandamide and 2AG are short-acting compounds, so their effects are fleeting.

In contrast, when a person consumes cannabis, a flood of THC molecules bind to thousands of CB1 and CB2 receptors, with longer-lasting effects. The binding triggers so many internal changes that, decades after the receptors’ discovery, scientists are still sorting out the effects. From a biological standpoint, smoking pot to get high is like starting up a semitruck just to listen to the radio. There’s a lot more going on.

Though the psychoactive effect of THC has slowed approval for cannabis-based drugs, the high might also have brought on a serendipitous discovery, says neurologist Ethan Russo, senior medical adviser for GW Pharmaceuticals, which is based in Porton Down, England. “How much longer would it have taken us to figure out the endocannabinoid system if cannabis didn’t happen to have these unusual effects on human physiology?”

Beyond the pain

Today smoked cannabis is a sanctioned self-treatment for verifiable medical conditions in 14 U.S. states, Canada, the Netherlands and Israel, among other places. It usually requires a doctor’s recommendation and some paperwork.

People smoke the drug to alleviate pain, sleep easier and deal with nausea, lack of appetite and mood disorders such as anxiety, stress and depression. Patients not wanting to smoke cannabis can seek out prescriptions for FDA-approved capsules containing cannabis compounds for treatment of some of these same problems.

Research now suggests that multiple sclerosis could join the growing list of cannabis-treated ailments. More than a dozen medical trials in the past decade have shown that treatments containing THC (and some that combine THC with another derivative called cannabidiol, or CBD) not only ease pain in MS patients but also alleviate other problems associated with the disease. MS results from damage to the fatty sheaths that insulate nerves in the brain and spinal cord.

“MS patients get burning pain in the legs and muscle stiffness and spasms that keep them awake at night,” says John Zajicek, a neurologist at the Peninsula College of Medicine and Dentistry in Plymouth, England. Patients can take potent steroids and other anti-inflammatory drugs, but the effects of these medications can be inconsistent.

Pertwee has analyzed 17 trials in which MS patients received some form of cannabis or its derivatives. Reports from the patients themselves, who didn’t know if they were getting real cannabinoids or a placebo in most of the trials, show improvements in muscle spasticity, sleep quality, shakiness, sense of well-being and mobility. Pertwee, who is also a consultant for GW Pharmaceuticals — which makes a cannabinoid drug that is delivered in spray form, called Sativex — reviewed the findings in Molecular Neurobiology in 2007.

Sativex was approved in Canada for MS in 2005 after studies (some included in Pertwee’s analysis) showed its success in relieving symptoms of the disease.

GW Pharmaceuticals expects clearance for MS treatment in the United Kingdom and Spain this year. Later, the company plans to seek U.S. approval of Sativex for cancer pain.

Zajicek’s team has also compared MS patients who received a placebo with patients receiving either a capsule containing THC or one with THC and CBD. Both of the cannabis-based drugs outperformed a placebo, and the researchers are now working on a multi year MS trial.

Calming symptoms such as muscle spasticity and pain is useful, Zajicek says, but the true value of cannabinoids may exceed that. “To me, the really exciting stuff is whether these drugs have a much more fundamental role in changing the course of MS over the longer term,” he says. “We’ve got nothing that actually slows progression of the disease.”

Fighting inflammation

CBD, the same cannabis component that proved beneficial alongside THC for MS, may also work on other hard-to-treat diseases. Tests on cell cultures and lab animals have revealed that CBD fights inflammation and mitigates the psychoactive effects of THC.

Crohn’s disease, which can lead to chronic pain, diarrhea and ulcerations, could be a fitting target for CBD. In Crohn’s disease, inflammatory proteins damage the intestinal lining, causing leaks that allow bacteria in the gut to spread where they shouldn’t. This spread leads to a vicious cycle that can trigger more inflammation.

Karen Wright, a pharmacologist at Lancaster University in England, and her colleagues have found that CBD inhibits this inflammation and can reverse the microscopic intestinal leakiness in lab tests of human cells. Adding THC doesn’t seem to boost the benefit, Wright reported in December 2009 in London at a meeting of the British Pharmacological Society. The results bolster earlier findings by Wright’s team showing that cannabinoids could improve wound healing in intestinal cells.

CBD’s anti-inflammatory effect may work, at least in some cases, through its antioxidant properties — the ability to soak up highly reactive molecules called free radicals, which cause cell damage.

In the brain and eye, CBD slows the action of microglia, immune cells that can foster harmful inflammation when hyperactivated by free radicals. Working with rats whose retinas were induced to have inflammation, biochemist Gregory Liou of the Medical College of Georgia in Augusta and his team found that CBD neutralized free radicals, preventing eye damage. This finding could have implications for people with diabetes who develop vision loss.

Apart from being an anti-inflammatory and antioxidant, CBD tones down the psychoactive effect of THC without eliminating its medical properties. CBD also mutes the occasional anxiety and even paranoia that THC can induce. This has been welcome news to scientists, who consider the “buzz” of cannabis little more than psychoactive baggage.

But CBD has paid a price for this anti-upper effect. “CBD has essentially been bred out of North American black market drug strains,” Russo says. People growing cannabis for its recreational qualities have preferred plants high in THC, so people lighting up for medical purposes, whether to boost appetite in AIDS patients or alleviate cancer pain, may be missing a valuable cannabis component.

Cannabis versus cancer

With or without CBD, cannabis may someday do more for cancer patients than relieve pain and nausea. New research suggests THC may be lethal to tumors themselves.

Biochemists Guillermo Velasco and Manuel Guzmán of Complutense University in Madrid have spent more than a decade establishing in lab-dish and animal tests that THC can kill cancer of the brain, skin and pancreas.

THC ignites programmed suicide in some cancerous cells, the researchers reported in 2009 in the Journal of Clinical Investigation. The team’s previous work showed that THC sabotages the process by which a tumor hastily forms a netting of blood vessels to nourish itself, and also keeps cancer cells from moving around.

THC achieves this wizardry by binding to protein receptors on a cancerous cell’s surface. Once attached, the THC induces the cell to make a fatty substance called ceramide, which prompts the cell to start devouring itself. “We see programmed cell death,” Velasco says. What’s more, noncancerous cells don’t make ceramide when they come into contact with THC. The healthy cells don’t die.

Many compounds kill cancer in a test tube and even in animals, but most prove useless because they cause side effects or just don’t work in people. The Madrid team is now seeking funding to test whether cannabis derivatives can kill tumors in cancer patients. In an early trial of nine brain cancer patients whose disease had worsened despite standard therapy, the scientists found that THC injections into tumors were safe to give.

Early reports from other research groups suggest that THC also fights breast cancer and leukemia. “I think the cancer research is extremely promising,” Russo says. “Heretofore, the model for cancer was to use an agent that’s extremely toxic to kill the cancer before it kills you. With cannabinoids, we have an opportunity to use agents that are selectively toxic to cancer cells.”

Looking ahead

Testing of cannabis and its derivatives has also begun on: type 1 diabetes, rheumatoid arthritis, stroke, Tourette syndrome, epilepsy, depression, bipolar disorder and schizophrenia. Pertwee is particularly optimistic that cannabis will help people with post-traumatic stress disorder. Experiments in rats show that THC “speeds up the rate at which the animals forget unpleasant experiences,” he says. And a recent study in people with PTSD showed that THC capsules improved sleep and stopped nightmares.

Despite these heady beginnings, medical cannabis still faces an uphill climb. Although some states have sanctioned its use, no smoked substance has ever been formally approved as a medicine by U.S. regulatory agencies. Smoking cannabis can lead to chronic coughing and bronchitis, and smoking renders a drug off-limits for children, Mechoulam notes.

THC pills don’t have these downsides, but the drugs have received only lukewarm acceptance. Despite smoking’s drawbacks, “it is seen as better because you can regulate the amount of THC you’re getting by not puffing as much,” says pharmacologist Daniele Piomelli of the University of California, Irvine. Capsules can cause dizziness and make it hard to focus. “Patients suffering from neuropathic pain or depression don’t want to be stoned — they want relief,” he says.

Controlled, randomized trials that seek to clarify whether smoked cannabis delivers on its medical promise — with acceptable side effects — have been hard to come by. But scientists in California have recently concluded several studies in which patients with severe pain received actual cannabis cigarettes or cannabis cigarettes with the cannabinoids removed.

In one trial, researchers randomly assigned 27 HIV patients to get the real thing and 28 to get fake joints. All the patients had neuropathic pain, in which neurons can overreact to even mild stimuli. About half of the people getting real cannabis experienced a pain reduction of 30 percent or greater, a standard benchmark in pain measurement. Only one-quarter of volunteers getting the placebo reported such a reduction.

“That’s about as good [a reduction] as other drugs provide,” says Igor Grant, a neuropsychiatrist at the University of California, San Diego, who is among the scientists overseeing the trials.

While such studies provide evidence that smoked marijuana has medical benefits, future trials are more likely to explore the benefits of cannabis derivatives that don’t carry the baggage that smoking does.

Ultimately, the fate of medical cannabis and its derivatives will rest on the same make-or-break requirements that every  experimental medicine faces — whether it cures a disease or alleviates its symptoms, and whether it’s tolerable.

“We have to be careful that marijuana isn’t seen as a panacea that will help everybody,” Grant says. “It probably has a niche.… We can’t ignore the fact that cannabis is a substance of abuse in some people.”

Getting cannabis in

When most people think of medicinal cannabis, smoking comes to mind. Though smoking works quickly and allows users to regulate their intake, it’s hardly a scientific approach: Cannabis quality is often unknown, and inhaling burned materials is bad for the lungs. These and other drawbacks have spawned new ways to consume medical marijuana.

Some people inhale cannabis by using a device that heats the plant without igniting it. This vaporization unleashes many of the same cannabinoid compounds as smoking does, without the combustion by-products, researchers say. Anecdotally, patients report that the effect is prompt, on a par with smoking.

Because cannabis derivatives can pass through the lining of the mouth and throat, a company called GW Pharmaceuticals has devised a spray product called Sativex. This drug contains roughly equal amounts of two key cannabinoids — THC and CBD — plus other cannabis components in an alcohol solution. A dose of Sativex is sprayed under the tongue; no smoking required.

In the face of these options, the “pot pill” seems almost passé. But capsules of synthetic THC exist. One called Marinol has been approved in the United States since 1985, and another called Cesamet was cleared more recently. Doctors can prescribe the drugs for nausea, vomiting, loss of appetite and weight loss. Though sales of capsules have increased recently, many users complain of psychoactive side effects and slow action.

-Suggested Reading :

* Mechoulam, R., et al. 2007. Cannabidiol – recent advances. Chemistry & Biodiversity 4:1678-1692.

Lakhan, S.E., and M. Rowland. 2010. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurology 9(Dec. 4):59. doi: 10.1186/1471-2377-9-59

Sparling, P.B., et al. 2003. Exercise activates the endocannabinoid system. NeuroReport, 14(December):2209-2211. DOI:10.1097/01.wnr.0000097048.56589.47

Zajicek, J., et al. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362(November):1517-1526.

Blázquez, C. et al. 2008. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Research 68(March 15):1945-1952.

Velasco, G., et al. 2007. Cannabinoids and gliomas. Molecular Neurobiology (Dec. 6). doi: 10.1007/s12035-007-0002-5

Johnson, J.R., et al. 2010. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management 39(February):167-79. doi: 10.1016/j.jpainsymman.2009.06.008

Liou, G.I. et al. 2008. Mediation of cannabidiol anti-inflammation in the retina by equiibrative nucleoside transporter and A2a adenosine receptor. Investigative Ophthalmology & Visual Science 49 (December): 5526-5531.

Liou, G.I. 2010. Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation. World Journal of Diabetes 1 (March 15):12-18. doi:10.4239/wjd.v1.i1.12

Holdcroft, A., et al. 2006. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for post-operative pain management. Anesthesiology 104 (May):1040-1046.

Hoffmann, D.E., and E. Weber. 2010. Medical Marijuana and the Law. New England Journal of Medicine 362(April 22):1453-1457.

Wade, D.T., et al. 2006. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis 12:639-645. DOI: 10.1177/1352458505070618

-Citations & References :

* A. Hazekamp and F. Grotenhermen. “Review on clinical studies with cannabis and cannabinoids 2005 – 2009.” Cannabinoids. 2010.
* Gaoni, Y. and R. Mechoulam. 1964. Isolation, structure and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86:1646-1647.

U.S. Drug Enforcement Agency. “Medical” Marijuana — The Facts.
[Go to]

Devane, W.A., et al. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34(November):605-613.

Devane, W.A., et al. 1992. Isolation and structure of brain constituent that binds to the cannabinoid receptor. Science 258 (Dec. 18):1946-1949.

Matsuda, L.A., et al. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (Aug. 9):561-564.

Gérard, C. M., et al. 1991. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemistry Journal 279(Oct. 1):129–134.

Mechoulam, R., et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50(June 29):83-90.

Abrahamov, A., et al. 1995. An efficient new cannabinoid anti-emetic in pediatric oncology. Journal of the International Hemp Association 2:76-79.
Pertwee, R.G. 2007. Cannabinoids and multiple sclerosis. Molecular Neurobiology, 36:45-59. doi: 10.1007/s12035-007-0005-2

Zajicek, J. P., et al. 2005. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. Journal of Neurology, Neurosurgery and Psychiatry 76:1664–1669. doi:10.1136/jnnp.2005.070136

Abrams, D. I., et al 2007. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 68:515-521.

El-Remessy, A.B., et al. 2008. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Molecular Vision, 14 (December):2190-2203. [Go to]

Salazar, M., et al. 2009. Cannabinoid action induces authophagy-mediated cell death through stimulaitohn of ER stress in human glioma cells. Journal of Clinical Investigation 119(May 1):1359-1372.

Borrelli, F., et al. 2009. Cannabdiol, a safe and non-psychoactive ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Journal of Molecular Medicine 87:1111-1121. doi:10.1007/s00109-009-0512-x

Wright, K., et al. 2005. Differential expression of cannabinoid receptor in the human colon: Cannabinoids promote epithelial wound healing. Gastroenterology 129:437-453. doi: 10.1053/j.gastro.2005.05.026

Wright, K.L, et al. 2007. Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. British Journal of Pharmacology 153(October): 263-270.

Shen, L., et al. 2009. Mechanisms and functional implications of intestinal barrier defects. Digestive Diseases 27:443-449.

Ganon-Elazar, E. and I. Akirav. 2009. Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. Journal of Neuroscience 29(Sept. 9):11078-11088. doi:10.1523/JNEUROSCI.1223-09.2009

Guzman, M., et al. 2006. A pilot study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer 95:197-203.

Blake, D.R., et al. 2005. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Nov. 9). doi:10.1093/rheumatology/kei183

Fraser, G. 2009. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience & Therapeutics 15:84-88.

Swift, W., et al. 2005. Survey of Australians using cannabis for medical purposes. Harm Reduction Journal 2(Oct. 4):18. doi: 10.1186/1477-7517-2-18

Ligresti, A., et al. 2006. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharmacology and Experimental Therapeutics 318(September):1375-1387. doi: 10.1124/jpet.106.105247

Jia, W., et al. 2006. Delta-9-tetrahydrocannabinol-induced apoptosis in jurkat leukemia T cells is regulated by translocation of bad to mitochondria. Molecular Cancer Research 4:549–562. doi: 10.1158/1541-7786.MCR-05-0193

McAllister, S.D., et al. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics 6(November):2921-2927. doi: 10.1158/1535-7163.MCT-07-0371

Hazekamp, A., et al. 2006. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of Pharmacological Science 95(June):1308-1317.

http://www.sciencen.comews.org/view/feature/id/59872/title/Not_just_a_high

Comments